Depakote Pregnancy Use May Cause Cognitive Impairment, FDA Warns

Federal drug regulators are warning that side effects of Depakote and other valproate-based epilepsy drugs may increase the risk that pregnant women will give birth to a child with impaired cognitive development. 

The FDA issued the Depakote pregnancy warning on June 30, 2011, after the agency analyzed the findings of studies that show children born to mothers who took Depakote while pregnant scored lower on cognitive tests than children whose mothers took other anti-seizure drugs while pregnant.

New warnings will be added to the label for Depakote and other related drugs, such as Depacon, Depakene and Stavzor, as well as their generic equivalents.

Did You Know?

Change Healthcare Data Breach Impacts Millions of Customers

A massive Change Healthcare data breach exposed the names, social security numbers, medical and personal information of potentially 100 million Americans, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Unless the use of a valproate-based drug is essential to avoid permanent injury or death, doctors should consider alternatives to Depakote for women of childbearing age, unless it is paired with effective birth control, the agency warned. Women already taking the drug should not stop using it until they talk with their healthcare professional.

The FDA warned that serious problems may occur when someone suddenly stops taking Depakote or other valproate-based drugs.

Depakote was approved in the United States in 1978 for treatment of certain forms of epilepsy. However, Depakote pregnancy use has been linked to an increased risk of a number of severe birth defects, especially when the drug is taken during the first 28 days, when neural tube closure and other critical formations are taking place.

In 2006, the FDA added a “black box” warning about the potential risk of Depakote birth defects after a study found that 20% of pregnant mothers who gave birth while on Depakote had a child with malformations or a birth defect. Birth defects associated with Depakote include spina bifida, cleft palate, abnormal skull development, malformed limbs, holes in the heart and urinary tract problems.

In May 2010, researchers found that Depakote problems for infants could occur after using the drug as early as the first trimester, which means that by the time many women discover they are pregnant, it could be too late to get off the drug and avoid birth defects for their unborn child.

In recent months, a growing number of Depakote lawsuits have been filed against Abbott Laboratories by families of children born with spina bifida and other birth defects or malformations.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

EU Launches Investigation Into Ozempic Vision Loss Problems
EU Launches Investigation Into Ozempic Vision Loss Problems (Posted yesterday)

Following nearly 20 reports of vision problems from Ozempic or Wegovy since a study was published in July 2024, Danish health officials are calling for an EU investigation into the safety of semaglutide-based drugs.